Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program.

Carpenter WR, Fortune-Greeley AK, Zullig LL, Lee SY, Weiner BJ.

Contemp Clin Trials. 2012 Jan;33(1):46-54. doi: 10.1016/j.cct.2011.09.007. Epub 2011 Oct 2.

2.

Performance in quasi-firms: an example from the Community Clinical Oncology Program.

Lacey LM, Hynes DM, Kaluzny AD.

J Health Hum Resour Adm. 1992 Winter;14(3):307-26.

PMID:
10118501
3.

Organizational and physician factors associated with patient enrollment in cancer clinical trials.

Jacobs SR, Weiner BJ, Reeve BB, Weinberger M, Minasian LM, Good MJ.

Clin Trials. 2014 Oct;11(5):565-75. doi: 10.1177/1740774514536000. Epub 2014 Jun 5.

4.

Predicting the performance of a strategic alliance: an analysis of the Community Clinical Oncology Program.

Kaluzny AD, Lacey LM, Warnecke R, Hynes DM, Morrissey J, Ford L, Sondik E.

Health Serv Res. 1993 Jun;28(2):159-82.

5.

Implementing community-based provider participation in research: an empirical study.

Teal R, Bergmire DM, Johnston M, Weiner BJ.

Implement Sci. 2012 May 8;7:41. doi: 10.1186/1748-5908-7-41.

6.

The effects of managed care and competition on community-based clinical research.

Carpenter WR, Weiner BJ, Kaluzny AD, Domino ME, Lee SY.

Med Care. 2006 Jul;44(7):671-9.

PMID:
16799362
7.

Organizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.

Weiner BJ, Jacobs SR, Minasian LM, Good MJ.

J Oncol Pract. 2012 Sep;8(5):287-91. doi: 10.1200/JOP.2011.000507. Epub 2012 May 1.

8.

Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program.

Kaluzny AD, Ricketts T 3rd, Warnecke R, Ford L, Morrissey J, Gillings D, Sondik EJ, Ozer H, Goldman J.

J Natl Cancer Inst. 1989 Nov 15;81(22):1717-25.

PMID:
2681795
9.

Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program.

Jacobs SR, Weiner BJ, Minasian LM, Good MJ.

Contemp Clin Trials. 2013 Mar;34(2):320-5. doi: 10.1016/j.cct.2012.12.008. Epub 2013 Jan 5.

10.
11.

Evaluating productivity in clinical research programs: the National Cancer Institute's (NCI) Community Clinical Oncology Program (CCOP).

Hynes DM, McLaughlin CP, Kaluzny AD, Ford LP, Sondik E.

J Med Syst. 1992 Dec;16(6):247-67.

PMID:
1304594
12.

Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.

Lyss AP, Lilenbaum RC.

Clin Lung Cancer. 2009 Nov;10(6):410-3. doi: 10.3816/CLC.2009.n.077.

PMID:
19900858
13.

A method for analyzing the business case for provider participation in the National Cancer Institute's Community Clinical Oncology Program and similar federally funded, provider-based research networks.

Reiter KL, Song PH, Minasian L, Good M, Weiner BJ, McAlearney AS.

Cancer. 2012 Sep 1;118(17):4253-61. doi: 10.1002/cncr.27375. Epub 2011 Dec 27.

14.
15.
16.

Using a community cancer treatment trials network for cancer prevention and control research: challenges and opportunities.

Kaluzny AD, Lacey LM, Warnecke R, Morrissey JP, Sondik E, Ford L.

Cancer Epidemiol Biomarkers Prev. 1994 Apr-May;3(3):261-9.

17.

Why providers participate in clinical trials: considering the National Cancer Institute's Community Clinical Oncology Program.

McAlearney AS, Song PH, Reiter KL.

Contemp Clin Trials. 2012 Nov;33(6):1143-9. doi: 10.1016/j.cct.2012.08.008. Epub 2012 Aug 19.

18.

Effect of state-mandated insurance coverage on accrual to community cancer clinical trials.

Ellis SD, Carpenter WR, Minasian LM, Weiner BJ.

Contemp Clin Trials. 2012 Sep;33(5):933-41. doi: 10.1016/j.cct.2012.06.001. Epub 2012 Jun 8.

19.
20.

Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program.

Kaluzny A, Brawley O, Garson-Angert D, Shaw J, Godley P, Warnecke R, Ford L.

J Natl Cancer Inst. 1993 Dec 1;85(23):1945-50.

PMID:
8230286

Supplemental Content

Support Center